[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
3. Ishikawa T: Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma. World J Gastroenterol; 2008 May 14;14(18):2797-801
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, including Japan.
  • Although the development of imaging modalities has made the early diagnosis of HCC possible, surgically resectable cases are relatively uncommon because of hepatic function reserve and/or an advanced stage at presentation.
  • Several modalities, such as transcatheter arterial chemoembolization, percutaneous ethanol injection, microwave coagulation therapy and radiofrequency ablation are reportedly useful in treating patients with non-resectable disease.
  • The overall prognosis of patients with HCC is very poor, and treatment of the advanced form is still problematic.
  • In this article, we review the clinical efficacy and toxicity of enteric-coated tegafur/uracil in the treatment of patients with advanced non-resectable HCC.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Administration, Oral. Humans. Tablets, Enteric-Coated. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol Hepatol. 2001 Apr;16(4):452-9 [11354285.001]
  • [Cites] Gan To Kagaku Ryoho. 2001 Apr;28(4):521-5 [11329788.001]
  • [Cites] Nihon Rinsho. 2001 Oct;59 Suppl 6:624-8 [11762024.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Nov;16(11):1274-81 [11903747.001]
  • [Cites] Gan To Kagaku Ryoho. 2003 Aug;30(8):1151-5 [12938272.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Oct;31(10):1555-8 [15508450.001]
  • [Cites] Gan. 1978 Dec;69(6):763-72 [750271.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 1):5405-12 [3931905.001]
  • [Cites] Clin Pharmacokinet. 1989 Apr;16(4):215-37 [2656050.001]
  • [Cites] Gan To Kagaku Ryoho. 1990 Jun;17(6):1211-6 [2112372.001]
  • [Cites] Gan To Kagaku Ryoho. 1990 Oct;17(10):2043-9 [2221928.001]
  • [Cites] Gan To Kagaku Ryoho. 1990 Nov;17(11):2183-90 [2241182.001]
  • [Cites] Am J Clin Oncol. 1995 Jun;18(3):204-10 [7747707.001]
  • [Cites] J Natl Cancer Inst. 1995 Aug 16;87(16):1262-3 [7563175.001]
  • [Cites] Gan To Kagaku Ryoho. 1996 May;23(6):773-7 [8645028.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3085-96 [8955653.001]
  • [Cites] Int J Oncol. 1998 Oct;13(4):653-7 [9735391.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):547-52 [10203589.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1682-5 [10364045.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2185-91 [10473104.001]
  • [Cites] Nature. 1957 Mar 30;179(4561):663-6 [13418758.001]
  • [Cites] J Biol Chem. 1961 Nov;236:3006-13 [13905041.001]
  • [Cites] Cancer Res. 1960 Jul;20:903-9 [14400597.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Dec;19(12):1423-6 [15610322.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Apr;32(4):469-72 [15853212.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Apr;32(4):523-7 [15853221.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):237-44 [16675478.001]
  • [Cites] World J Gastroenterol. 2007 Nov 7;13(41):5465-70 [17907289.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Jan;27(1):93-8 [10660738.001]
  • [Cites] Gan To Kagaku Ryoho. 2001 Aug;28(8):1137-40 [11525032.001]
  • (PMID = 18473401.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Tablets, Enteric-Coated; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC2710718
  •  go-up   go-down


Advertisement
4. Alvarez R, Bañares R, Echenagusía A, Carneros JA, Santos L, Simó G, Camúñez F: [Prognostic factors for survival following transarterial chemoembolization in advanced hepatocellular carcinoma]. Gastroenterol Hepatol; 2000 Apr;23(4):153-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors for survival following transarterial chemoembolization in advanced hepatocellular carcinoma].
  • [Transliterated title] Factores pronósticos de supervivencia del carcinoma hepatocelular avanzado tras quimioembolización transarterial.
  • The efficacy of transarterial chemoembolization in the palliative treatment of non-resectable hepatocellular carcinoma is controversial.
  • To determine the possible existence of clinical and analytical variables with independent predictive value for survival related to the tumor and the treatment given, a multivariate analysis in a series of 111 patients who underwent transarterial chemoembolization was carried out.
  • Child-Pugh score (p < 0.05), tumor size (p < 0.05) and arterial occlusion after intraarterial chemotherapy (p < 0.05) reached independent predictive value.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10863854.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] SPAIN
  •  go-up   go-down


5. Lubienski A, Bitsch RG, Schemmer P, Grenacher L, Düx M, Kauffmann GW: [Long-term results of interventional treatment of large unresectable hepatocellular carcinoma (HCC): significant survival benefit from combined transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) compared to TACE monotherapy]. Rofo; 2004 Dec;176(12):1794-802
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of interventional treatment of large unresectable hepatocellular carcinoma (HCC): significant survival benefit from combined transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) compared to TACE monotherapy].
  • [Transliterated title] Langzeitergebnisse der interventionellen Therapie von grossen, inoperablen hepatozellulären Karzinomen (HCC): signifikanter Uberlebensvorteil von transarterieller Chemoembolisation (TACE) und perkutaner Ethanolinjektion (PEI) gegenüber der TACE-Monotherapie.
  • PURPOSE: A retrospective analysis of long-term efficacy of combined transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) and TACE monotherapy was conducted in patients with large, non-resectable hepatocellular carcinoma (HCC).
  • Liver cirrhosis was present in 42 patients, due to alcohol abuse (n = 22) and viral infection (n = 17).
  • In three patients, the underlying cause for liver cirrhosis remained unclear.
  • The kind of treatment significantly affected the survival rate (p = 0.002 log-rank test).
  • Severe side effects were present in two patients of the monotherapy group and in three patients of the combination therapy group.
  • CONCLUSION: The combination of TACE and PEI is an effective and safe method in the palliative treatment of large HCC that has the potential of improving long term survival compared to TACE monotherapy.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Ethanol / administration & dosage. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Data Interpretation, Statistical. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Injections, Subcutaneous. Liver Cirrhosis / complications. Male. Middle Aged. Palliative Care. Retrospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15573291.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3K9958V90M / Ethanol
  •  go-up   go-down


6. Voiculescu M, Winkler RE, Moscovici M, Neuman MG: Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic. J Gastrointestin Liver Dis; 2008 Sep;17(3):315-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic.
  • Chronic liver diseases alone or in conjunction with other risk factors result in increased liver damage leading to inflammation and fibrosis of the liver and rising rates of liver cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC).
  • This review will address the determinants of liver injury at the initiation of the tumor and the risk factors for rapid disease progression.
  • Liver disease is often associated with enhanced hepatocyte apoptosis, which is the case in viral and autoimmune hepatitis, cholestatic diseases, and metabolic disorders.
  • The mechanisms by which apoptosis occurs in the liver might provide insights into HCC and suggest possible treatments.
  • This review will also aim to describe the molecular targeted therapies of non-resectable HCC and the ways of effective combination in this otherwise chemo-resistant tumor.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis. Drug Delivery Systems. Humans. Liver Diseases / complications. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836626.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 89
  •  go-up   go-down


7. Uka K, Aikata H, Takaki S, Kawaoka T, Saneto H, Miki D, Takahashi S, Toyota N, Ito K, Chayama K: Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. World J Gastroenterol; 2008 Apr 28;14(16):2602-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.
  • The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC).
  • Systemic gemcitabine chemotherapy seems effective in many cancers.
  • We report the results of combination therapy with systemic gemcitabine, intra-arterial low-dose cisplatin and 5-FU (GEMFP).
  • Seven patients with non-resectable advanced HCC were treated with GEMFP.
  • One course of chemotherapy consisted of daily intra-arterial cisplatin (20 mg/body weight/hour on d 1, 10 mg/body weight per 0.5 h on d 2-5 and 8-12), followed by 5-FU (250 mg/body weight per 5 h on d 1-5 and 8-12) via an injection port.
  • With regard to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 3 or 4 adverse reactions, seven (100%), seven, six (86%) and one (14%) patients developed leukopenia, neutropenia, thrombocytopenia and anemia, respectively.
  • GEMFP may potentially be effective for non-resectable advanced HCC, but it has severe hematologic toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Patient Selection. Survival Analysis. Survivors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):129-37 [17508408.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1209-16 [17919232.001]
  • [Cites] J Gastroenterol. 2007 Oct;42(10):845-53 [17940838.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):435-42 [11900229.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):588-95 [12209752.001]
  • [Cites] Am J Surg. 2002 Sep;184(3):284-90 [12354601.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2666-70 [14669309.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Dec;9(12):1841-50 [6319339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 [3466165.001]
  • [Cites] Cancer Res. 1987 Sep 15;47(18):4967-72 [3040235.001]
  • [Cites] Cancer. 1988 May 15;61(10):1983-7 [2834036.001]
  • [Cites] Ann Surg. 1988 Jul;208(1):23-35 [2839123.001]
  • [Cites] Am J Clin Oncol. 1989 Oct;12(5):397-401 [2801599.001]
  • [Cites] Eur J Surg Oncol. 1992 Apr;18(2):156-61 [1316289.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):52-6 [8318420.001]
  • [Cites] Cancer. 1997 May 15;79(10):1890-6 [9149014.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2087-94 [9179054.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Hepatology. 1999 Jan;29(1):62-7 [9862851.001]
  • [Cites] Br J Cancer. 2005 Sep 5;93(5):557-64 [16106266.001]
  • [Cites] Trop Gastroenterol. 2005 Jul-Sep;26(3):115-8 [16512457.001]
  • [Cites] J Med Virol. 2006 Apr;78(4):459-65 [16482557.001]
  • [Cites] Cancer. 2006 May 1;106(9):1990-7 [16565970.001]
  • [Cites] World J Gastroenterol. 2007 Jan 21;13(3):414-20 [17230611.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1384-90 [17330837.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):750-6 [10951336.001]
  • (PMID = 18442216.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2708380
  •  go-up   go-down


8. Park JW, Korean Liver Cancer Study Group and National Cancer Center: [Practice guideline for diagnosis and treatment of hepatocellular carcinoma]. Korean J Hepatol; 2004 Jun;10(2):88-98
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Practice guideline for diagnosis and treatment of hepatocellular carcinoma].
  • BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is the 3rd most common cancer.
  • While hepatitis B virus is major cause of Korean HCC, the impact of alcoholic liver disease is a rising trend.
  • The 5-year survival rate of HCC is only 9.6%, mainly due late diagnosis, tumor biology and underlying chronic liver diseases.
  • Because almost eighty percent of HCC is diagnosed in late, not early stages, a nationwide surveillance program to screen high risk groups (HBV or HCV carriers or liver cirrhosis, over 40 years old) was launched last year and a practice guideline, with special emphasis on advanced stage HCC was formulated.
  • Based on scientific evidence, the consensus was made for diagnosis and treatment strategy after considering the medico-social situation in Korea.
  • RESULTS: Required and optional tests and clinical (non-invasive) diagnosis criteria for HCC are identified.
  • The first decision, based on both Child-Pugh score and modified UICC tumor staging, is to determine operability.
  • The second decision, to determine resectability, is based on localization of the tumor and residual liver function.
  • Chemoembolization or local ablation therapy is allowed for resectable tumors in certain conditions, such as at borderline risk or non-invasively diagnosed.
  • Unresectable tumors are classified into either a group with inadequate residual liver functions or the another group with extensive or macrovascular invasion or distant metastases.
  • Indications of liver transplantation, chemoembolization, local ablation, radiation therapy and chemotherapy for unresectable HCC are presented.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15218342.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Guideline; Journal Article; Practice Guideline
  • [Publication-country] Korea (South)
  •  go-up   go-down


9. García-Leiva J, Gamboa-Domínguez A, Ceron-Lizarraga T, Morales-Espinosa D, Meza-Junco J, Arrieta O: Response of negative estrogen-receptor hepatocarcinoma to tamoxifen, and survival of non-resectable patients. Ann Hepatol; 2006 Oct-Dec;5(4):263-7
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of negative estrogen-receptor hepatocarcinoma to tamoxifen, and survival of non-resectable patients.
  • Hepatocellular carcinoma is the fifth most common malignant neoplasm worldwide.
  • Most patients are not candidates to surgical treatment.
  • Estrogen receptors have been found in up to 33% of this tumors, reason why treatment with tamoxifen or progesterone compounds have been tried to diminish this neoplasm's progression but its use remains controversial.
  • The multivariate analysis showed that treatment with tamoxifen duplicates survival independently of the tumoral stage and functional hepatic reserve.
  • It seems that the benefit of treatment with tamoxifen is limited and is not associated to the presence of estrogen receptors.
  • In our study a 69 year-old man with diagnosis of non-resectable hepatocellular carcinoma and negative estrogen receptors, was treated with tamoxifen with a partial response and an overall survival of 4 years until November 2005.
  • It is important to identify patients that would benefit from treatment with tamoxifen.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Receptors, Estrogen / antagonists & inhibitors. Tamoxifen / therapeutic use
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Retrospective Studies. Sex Factors. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17151578.001).
  • [ISSN] 1665-2681
  • [Journal-full-title] Annals of hepatology
  • [ISO-abbreviation] Ann Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


10. Pohl J, Zuna I, Stremmel W, Rudi J: Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy; 2001 Sep-Oct;47(5):359-65
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma.
  • BACKGROUND: The purpose of this retrospective study was to determine the response rate and effect on survival of chemotherapy with epirubicin in non-resectable advanced hepatocellular carcinoma (HCC).
  • METHODS: Fifty-two patients with non-resectable disease were treated with epirubicin.
  • A treatment cycle consisted of 20 mg/m(2) i.v. on days 1, 8 and 15 and was repeated every 4 weeks to a maximum dose of 1,000 mg/m(2).
  • For patients with successful disease control (complete and partial responders and patients with SD), the median survival was 16.2 months; for non-responders, it was 6.1 months (p < 0.003).
  • CONCLUSION: Epirubicin appears to be an active therapeutic option for patients with non-resectable HCC.
  • Especially the subgroup of patients with low levels of AFP may benefit from this treatment.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Epirubicin / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11561139.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


11. Wang Y, Jin Y, Zhang Z: [Radiotherapy and intra-arterial chemotherapy of locally advanced hepatocellular carcinoma. Analysis of prognostic factors]. Cancer Radiother; 2000 May-Jun;4(3):191-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiotherapy and intra-arterial chemotherapy of locally advanced hepatocellular carcinoma. Analysis of prognostic factors].
  • [Transliterated title] Radiothérapie et chimiothérapie intra-artérielle des carcinomes hépatocellulaires localement évolués. Analyse des facteurs pronostiques.
  • Prognostic factors in the treatment of local advanced hepatocellular carcinoma with radiotherapy, transcatheter arterial embolization and arterial infusion.
  • PURPOSE: The treatment effects of radiotherapy and combination modality therapy for the local advanced hepatocellular carcinoma (HCC) were retrospectively reviewed.
  • 2) Bi-therapeutic method: hepatic artery ligation (HAL) and/or hepatic artery embolization (HAE) plus radiotherapy; and 3) tri-therapeutic method (bi-therapeutic method plus hepatic artery infusion) from 1975 to 1996.
  • RESULTS: There were no significant differences among these three treatment groups in the symptom relief rate, but the mean relief time period was much shorter in radiotherapy alone group (2.5 vs 44 months, P < 0.05).
  • There were evident differences in five-year survivals among these three treatment groups: 0% for radiotherapy alone, 22.8% for bi-therapeutic method and 38.8% for tri-therapeutic method (P < 0.01).
  • CONCLUSION: Non-resectable local advanced HCC can be treated by the combination modality therapy, including radiotherapy, with a quite high cure rate.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / drug therapy. Liver Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Injections, Intra-Arterial. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10897761.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Jakab F: [Surgical treatment of hepatocellular carcinoma]. Orv Hetil; 2004 Sep 12;145(37):1891-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of hepatocellular carcinoma].
  • [Transliterated title] A hepatocellularis carcinoma sebészi kezelése.
  • Surgical treatment of hepatocellular carcinoma.
  • The therapy of hepatocellular carcinoma (HCC) has got nowadays an important problem of medicine.
  • The five year survival time has increased in the consequences of the last 25 year medical activities.
  • The development of liver surgery, the introduction of aggressive surgical strategy, the prognosis of the disease and the special indication of the operation have had important factors in bettering of the results.
  • The size and number of the tumor, the tumor-free region of the tissue resected, capsule building, and the venous infiltration are the most important factors influencing the survival time.
  • The repeated resection in case of newly developed HCC has got also a result with 19-20 per cent of five year survival time.
  • In cases of non resectable tumors the a la carte chemotherapy, radiofrequency, TACE for down staging produce an opportunity in 10-20% of tumors being resectable.
  • The new combined surgical-oncologic-intervention strategies involve the two step and repeated interventions, the minimal invasive technique (MIT), the TACE and the a la carte chemotherapy.
  • Liver transplantation can be carried out exclusively in tumors less than 3 cm and in those having no more than 3 metastases.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Hepatectomy. Humans. Liver Transplantation. Predictive Value of Tests. Prognosis. Reoperation. Risk Factors. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493619.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 23
  •  go-up   go-down


13. Cusnir M, Patt YZ: Novel systemic therapy options for hepatocellular carcinoma. Cancer J; 2004 Mar-Apr;10(2):97-103
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel systemic therapy options for hepatocellular carcinoma.
  • Hepatocellular carcinoma, a common malignancy globally, has been increasing in incidence in the United States, mostly due to the rising incidence of Hepatitis C viral (HCV) infection.
  • However, orthotopic liver transplantation (OLT) has been associated with long-term survival benefit and cures, provided rigorous patient-selection criteria were adhered to.
  • Liver cirrhosis is the most common precursor for HCC, and attempts have been made to prevent the progression from liver cirrhosis to HCC.
  • Post resection adjuvant therapies have included interferon, polyprenoic acid, and adoptive immunotherapy.
  • Finding effective systemic treatments for non-resectable HCC has been challenging and quite frustrating.
  • The presence of liver cirrhosis and the associated volume expansion, electrolyte imbalances, decreased liver synthetic and metabolic reserve, and portal hypertension has made the design of systemic therapy for HCC a major challenge.
  • Additionally staging of HCC using the Tumor Node Metastases (TNM) system, but ignoring the underlying liver disease made it extremely difficult to compare results of different trials.
  • However by and large it would seem, that the more aggressive chemotherapy agents and combinations were associated with median survival times of 3-5 months.
  • Considering the vascular nature of HCC it may be reasonable to combine tolerable chemotherapy with newly released agents with angiogenesis inhibiting properties.
  • Thus, systemic therapy of HCC is a work in progress that calls for additional trials of tolerable newer agents and combinations.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cancer Vaccines / administration & dosage. Chemotherapy, Adjuvant. Humans. Interferons / therapeutic use. Retinoids / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15130269.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Retinoids; 9008-11-1 / Interferons
  • [Number-of-references] 73
  •  go-up   go-down


14. Sturm JW, Keese M: Multimodal treatment of hepatocellular carcinoma (HCC). Onkologie; 2004 Jun;27(3):294-303
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal treatment of hepatocellular carcinoma (HCC).
  • Screening of patients at risk for hepatocellular carcinomas (HCC) and preventive virustatic therapy are the first steps in a multimodal treatment concept, because delayed detection leads to a poor prognosis with median survival of <10 months.
  • Surgical resection of HCC is still the treatment of choice in patients with good residual liver function, however, recurrence-free 5-year survival after curative resection is low (33%).
  • In patients with cirrhosis, only 25% of HCC are resectable, limited by low hepatic functional reserve.
  • HCC in patients with non-cirrhotic livers are the domain of extended resections.
  • A new option in HCC therapy are the local methods for tumor ablation, preferably radiofrequency ablation (RFA), especially in patients with limited liver function, non-resectable or multifocal tumors.
  • Controlled randomized studies comparing and validating the different methods and defining combined treatments according to liver function and tumor stage are eagerly awaited.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Risk Assessment / methods
  • [MeSH-minor] Combined Modality Therapy / methods. Humans. Patient Care Management / methods

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger GmbH, Freiburg
  • (PMID = 15249721.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 88
  •  go-up   go-down


15. Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Ota H, Nakamura M, Wada H, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshit K, Nakamori S, Monden M: Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology; 2007 Jan-Feb;54(73):172-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch.
  • BACKGROUND/AIMS: The prognosis of hepatocellular carcinoma (HCC) invading the major branches of the portal vein (Vp3) is extremely poor.
  • Recently, we reported the efficacy of combination therapy with subcutaneous interferon (IFN)-alpha and intra-arterial 5-FU for intractable HCC with Vp3.
  • In this study, this therapy was applied for resectable advanced HCC (Vp3) as a postoperative adjuvant.
  • Fifteen consecutive patients with HCC and Vp3 were treated with at least 3 cycles of a combination therapy consisting of continuous arterial infusion of 5-FU (300 mg/mm3/day, 5 days/week, for the initial 2 weeks) and subcutaneous injection of IFN (5 MIU, 3 times/week, 4 weeks) as a postoperative adjuvant therapy following hepatic resection.
  • Another 15 patients who underwent hepatic resection with no IFN/5-FU chemotherapy acted as controls.
  • RESULTS: The results were as follows in the IFN/5-FU adjuvant treatment group; disease-free survival (n=11, 5-55 months), survival with recurrence (n=2, 9, 48 months), cancer death (n=1, 18 months), death from other causes but no recurrence (n=l, 22 months).
  • CONCLUSIONS: Combination therapy with subcutaneous IFN and intra-arterial perfusion of 5-FU seems to be a promising postoperative adjuvant treatment modality for resectable HCC with Vp3.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Fluorouracil / therapeutic use. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy. Venous Thrombosis / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / therapeutic use. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Hepatectomy. Humans. Infusions, Intra-Arterial. Injections, Subcutaneous. Male. Middle Aged. Neoplasm Invasiveness. Portal Vein / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419255.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antimetabolites, Antineoplastic; 0 / Interferon-alpha; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Popescu I, Alexandrescu S, Ciurea S, Brasoveanu V, Hrehoret D, Gangone E, Boros M, Herlea V, Croitoru A: Adrenalectomy for metastases from hepatocellular carcinoma - a single center experience. Langenbecks Arch Surg; 2007 May;392(3):381-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenalectomy for metastases from hepatocellular carcinoma - a single center experience.
  • BACKGROUND: Adrenal metastases (AM) from hepatocellular carcinoma (HCC) are rarely seen in clinical practice.
  • The treatment is not standardized, the indications and efficacy of different therapeutic approaches being still controversial.
  • PATIENTS: Between January 1995 and December 2005, 174 patients underwent liver resection for HCC in our center.
  • AM were detected in four patients (2.3%): three of them had HCC and synchronous AM, and the remaining one developed AM 10 months after liver resection.
  • All the patients with AM were treated by adrenalectomy (simultaneously with liver resection in synchronous metastases), followed by systemic chemotherapy.
  • Non-resectable multifocal liver recurrences occurred in two patients, one of them having also a contralateral adrenal metastasis; these two patients are presently alive 26 and 43 months after adrenalectomy, respectively.
  • Another patient died by liver recurrence 27 months postoperatively.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2002;32(12):1035-41 [12541019.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2523-8 [10522032.001]
  • [Cites] Chirurgie. 1998 Jun;123(3):280-6 [9752519.001]
  • [Cites] Kaohsiung J Med Sci. 2005 Aug;21(8):371-6 [16158880.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):863-77 [6295617.001]
  • [Cites] World J Surg Oncol. 2005 Jul 25;3:50 [16042808.001]
  • [Cites] Dig Surg. 2001;18(4):294-7 [11528139.001]
  • [Cites] Radiology. 1992 Jun;183(3):785-6 [1584934.001]
  • [Cites] Jpn J Clin Oncol. 1989 Mar;19(1):62-6 [2537908.001]
  • [Cites] Gan No Rinsho. 1987 Feb;33(2):199-204 [3031333.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):249-51 [11941967.001]
  • [Cites] Kurume Med J. 2003;50(1-2):41-8 [12971262.001]
  • [Cites] Jpn J Clin Oncol. 2005 Feb;35(2):61-7 [15709088.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1036-41 [10370663.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):316-9 [7691699.001]
  • (PMID = 17187285.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Van De Wiele C, Defreyne L, Peeters M, Lambert B: Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors. Q J Nucl Med Mol Imaging; 2009 Jun;53(3):317-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors.
  • Neither regional nor systemic chemotherapy significantly improve survival in the majority of patients presenting with liver metastases and their median survival is short.
  • While the incidence of hepatocellular (HCC) is increasingly worldwide, the various treatment approaches that hve been developed to treat non-resectable HCC have had minimal or moderate impact on overall survival.
  • SIR-Spheres (SIRS) are commercially available (90)Y-labelled resin microspheres that when selectively injected via the hepatic artery will become trapped in the tumor caplliary bed and will selectively deliver radiation to the tumor whilst sparing normal tissue.
  • First, available, predominantly phase I and II studies, on SIRS treatment performed in patients suffering from liver metastases as well as in patients suffering from multinodular asymptomatic unresectable HCC with a well preserved liver function have consistently reported a favourable safety profile for SIRS therapy; only a limited number of patients develop gastrointestinal ulceration or bleeding.
  • Second, most of the studies also reported a high reponse rate to SIRS treatment resulting in increased life expectancy; median survival rates proved consistently higher when compared to historical controls.
  • Finally, in two randomized controlled phase III trials, benefits were demonstrated for SIRS combined with chemotherapy when compared to the chemo-arm alone in patients suffering from colorectal liver metastasis.
  • However, since these reports, novel, potentially more effective chemotherapeutics have been introduced for treating colorectal liver metastasis and the clinical value of (90)Y-Sirspheres when compared to these novel chemotherapeutics warrants confirmation and validation.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Carcinoma, Hepatocellular / secondary. Liver Neoplasms / radiotherapy. Radioisotopes / administration & dosage. Resins, Synthetic / chemistry. Yttrium Radioisotopes / administration & dosage. Yttrium Radioisotopes / chemistry
  • [MeSH-minor] Drug Carriers / chemistry. Humans. Microspheres. Radiopharmaceuticals / administration & dosage. Radiopharmaceuticals / chemistry. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19521311.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Resins, Synthetic; 0 / Yttrium Radioisotopes
  • [Number-of-references] 28
  •  go-up   go-down


19. Mondragón-Sánchez R, Garduño-López AL, Hernández-Castillo E, Gómez-Gómez E, Ruiz-Molina JM: Hepatocellular carcinoma and hepatitis C in Mexico. Hepatogastroenterology; 2005 Jul-Aug;52(64):1159-62
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma and hepatitis C in Mexico.
  • BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) has increased in many countries as a result of an increased frequency of hepatitis C virus (HCV) infection.
  • This study aims to evaluate the epidemiological factors related to HCC in Mexican patients as well as the results of treatment.
  • Thirteen were treated with intraoperative large volume ethanol injection (ILVEI), 12 with chemotherapy and 19 with tamoxifen-talidomide.
  • Patients without treatment had a median survival time of 11 months and patients who received treatment had a median survival time of 25.3 months.
  • The median survival time in patients who received surgery was 26 months, the ILVEI group survival time was 18 months, the chemotherapy survival was 8.8 months, and the tamoxifen-talidomide survival time was 7 months.
  • Surgical resection is the best form of treatment of HCC in our country.
  • For non-resectable lesions, ILVEI offers the best palliative results in our center.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Hepatitis C / complications. Liver Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Hepatitis B / complications. Humans. Incidence. Liver Cirrhosis, Alcoholic / complications. Male. Mexico / epidemiology. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001652.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


20. Kirchhoff TD, Rudolph KL, Layer G, Chavan A, Greten TF, Rosenthal H, Kubicka S, Galanski M, Manns MP, Schild H, Gallkowski U: Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol; 2006 Mar;32(2):201-7
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial.
  • AIMS: Transarterial chemoembolization (TACE) can be associated with considerable toxicity and treatment-associated mortality.
  • METHODS: Seventy-four patients with advanced HCC were randomised to two treatment arms: (i) TACO (600-1200 mg DSM) and (ii) TACP.
  • In both arms regional chemotherapy consisted of cisplatin (100 mg/m2) and doxorubicin (60 mg/m2).
  • Both arms were corresponding in terms of age, gender, liver performance state, and tumour-stage.
  • A maximum of six treatment cycles was applied in monthly intervals.
  • Follow-up was performed in terms of tumour response, time to progression, survival and quality of life.
  • RESULTS: Tumour response rates did not differ significantly between the two treatment arms, however, there was a tendency towards higher response rates in the TACO arm (TACO vs TACP): partial response: 26 vs 9%, stable disease: 41 vs 55%, progressive disease: 33 vs 36%.
  • Time to tumour progression (32 vs 27 weeks), and overall survival (60 vs 69 weeks) were not significantly different.
  • Grade 4 adverse events were rare in both arms and treatment-associated mortality was not observed.
  • In addition, there was no significant difference in terms of quality of life under therapy (EORTC).
  • CONCLUSION: TACO with DSM did not improve response or survival significantly compared to TACP in advanced non-resectable HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Chemotherapy, Cancer, Regional Perfusion. Liver Neoplasms / therapy. Starch / therapeutic use
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Quality of Life. Survival Analysis. Treatment Outcome. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373084.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / degradable starch microspheres; 80168379AG / Doxorubicin; 9005-25-8 / Starch; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Lu W, Li YH, He XF, Zhao JB, Chen Y, Mei QL: Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization. Cardiovasc Intervent Radiol; 2008 Nov-Dec;31(6):1133-40
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization.
  • Our purpose was to study necrosis and apoptosis of hepatocellular carcinoma (HCC) cells after preoperative transcatheter arterial chemoembolization (TACE) with use of low-dose and high-dose anticancer drugs in HCCs.
  • Fifty-four patients with advanced but surgically resectable HCC were studied.
  • Patients in group A (n = 16) received low-dose anticancer drugs: 2 mg mitomycin C (MMC), 10 mg epirubicin (EPI), and 100 mg carboplatin (CBP).
  • Patients in group B (n = 18) were given high doses of anticancer drugs (10 mg MMC, 40 mg EPI, and 300 mg CBP).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Apoptosis. Biomarkers, Tumor / analysis. Carboplatin / administration & dosage. Chi-Square Distribution. Combined Modality Therapy. Disease Progression. Dose-Response Relationship, Drug. Epirubicin / administration & dosage. Female. Humans. Liver Function Tests. Male. Middle Aged. Mitomycin / administration & dosage. Necrosis. Statistics, Nonparametric. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18584240.001).
  • [ISSN] 1432-086X
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; BG3F62OND5 / Carboplatin
  •  go-up   go-down


22. Locker GJ, Mader RM, Steiner B, Wenzl E, Zielinski CC, Steger GG: Benefit of interferon-alpha2b in a patient with unresectable hepatoma and chronic infection with hepatitis C virus. Eur J Gastroenterol Hepatol; 2000 Feb;12(2):251-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only in a small proportion of patients is advanced hepatocellular carcinoma (HCC) resectable, so the need for effective non-surgical treatments is obvious.
  • Within a few weeks, a partial tumour remission, paralleled by a decrease in serum levels of tumour markers and liver enzymes, was observed.
  • Interferon-alpha might serve as a treatment option in patients with unresectable hepatoma and chronic active viral hepatitis, but prospective studies are warranted.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10741945.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


23. Fan XY, Uchida H, Iwaki K, Kai S, Shibata K, Ohta M, Kitano S: [Anti-tumor effects of various interferons-alpha +5-fluorouracil via downregulation of dihydropyrimidine dehydrogenase in hepatoma cells]. Gan To Kagaku Ryoho; 2007 Jun;34(6):957-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Systemic chemotherapy has not seen widespread use in the treatment for hepatocellular carcinoma (HCC).
  • Recently, it was reported that combination treatment of 5-fluorouracil (5-FU) and interferon (IFN)-alpha was effective for non-resectable HCC.
  • The effect of 5-FU treatment is influenced by the activities of pyrimidine catabolic enzymes.
  • The aim of this study was to investigate which IFN-alphais most effective in combination therapy via downregulation of dihydropyrimidine dehydrogenase (DPD).
  • METHODS: Cell proliferation assay in human hepatoma cells (HepG 2) was performed using 5-FU and/or various IFNs-alpha (C-IFN, Intron A, OIF).
  • At the same time,DPD mRNA levels were quantified by real-time polymerase chain reaction.
  • C-IFN +5-FU most effectively prevented cancer cell proliferation (p < 0.05).
  • C-IFN may be most effective in the combination therapy of IFN-alpha +5-FU for HCC.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Carcinoma, Hepatocellular / pathology. Dihydrouracil Dehydrogenase (NADP) / metabolism. Fluorouracil / pharmacology. Interferon-alpha / pharmacology. Liver Neoplasms / pathology
  • [MeSH-minor] Cell Division. Cell Line, Tumor. Down-Regulation. Humans

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565266.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Interferon-alpha; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); U3P01618RT / Fluorouracil
  •  go-up   go-down


24. András C, Szúcs Farkas Z, Csiki Z, Gál I, Takács I, Sápy P, Péter M: [Clinical evaluation of local lipiodol chemoembolization therapy in primary and secondary hepatic tumors]. Orv Hetil; 2000 Aug 6;141(32):1773-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical evaluation of local lipiodol chemoembolization therapy in primary and secondary hepatic tumors].
  • The authors treated with locoregional lipiodol chemoembolization 32 patients suffering from primary and secondary liver malignancies.
  • They present the clinical results of the 22 patients who received at least 2 treatments.
  • Seven patients suffered from primary liver carcinoma; regarding the Child's staging of the tumors 4 patients were in Child A, 3 patients in Child B.
  • In 15 cases the treatment indication was secondary liver cancer.
  • The primary tumors in these secondary liver cancer cases were: one case lung cancer, 11 colon (2 cases rectum) cancer, 2 cases pancreas cancer, one case gastric carcinoma.
  • The 22 patients received in total 97 cycles of therapy.
  • During the mean follow up time of 9 months (3-15 months) remission could be observed in 6/22 patients.
  • It can be concluded that in the case of well-selected cases of non-resectable liver malignancies local chemoembolization could be beneficial, as it could slow down the progression of the underlying disease with the maintainment or even improvement of the quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Chemoembolization, Therapeutic / methods. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Hepatic Artery. Humans. Infusions, Intra-Arterial. Iodized Oil. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10979306.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] HUNGARY
  • [Chemical-registry-number] 8001-40-9 / Iodized Oil
  •  go-up   go-down


25. Mulder K, Koski S, Scarfe A, Chu Q, King K, Spratlin J: Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget; 2010 Nov;1(7):515-29
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced gastrointestinal (GI) malignancies are varied in presentation, prognosis, and treatment options.
  • With the exception of resectable recurrent colorectal cancer, metastatic GI malignancies are incurable.
  • Cytotoxic chemotherapies have been the mainstay of therapy for decades but limited extension of survival or clinical benefit has been achieved in non-colorectal GI cancers.
  • Clear benefits have been identified with bevacizumab and sorafenib in colorectal cancer and hepatocellular cancer, respectively; other GI tumor sites have lacked impressive results with antiangiogenic agents.
  • In this review, we will present the benefits, or lack thereof, of clinically tested antiangiogenic compounds in GI malignancies and explore some potential new therapeutic anti-angiogenesis options for these diseases.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma / drug therapy. Gastrointestinal Neoplasms / drug therapy. Medical Oncology / trends
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Biliary Tract Neoplasms / drug therapy. Biliary Tract Neoplasms / pathology. Disease Progression. Drugs, Investigational / therapeutic use. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Models, Biological. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Protein Kinase Inhibitors / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):60-5 [12506171.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3121-6 [12810638.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4221-6 [14519649.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):879-83 [14624781.001]
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):643-8 [14991930.001]
  • [Cites] J Clin Invest. 2004 Apr;113(7):1040-50 [15057311.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):211-20 [10343072.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1630-4 [10408410.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3B):2257-60 [10472340.001]
  • [Cites] Expert Opin Pharmacother. 2005 Feb;6(2):211-23 [15757418.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):179-86 [15863033.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3697-705 [15738537.001]
  • [Cites] Br J Cancer. 2005 Jun;92 Suppl 1:S14-20 [15928653.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1391-7 [15905307.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):483-9 [16052530.001]
  • [Cites] Oncology. 2005;69 Suppl 3:11-6 [16301831.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] Oncologist. 2005;10 Suppl 3:40-8 [16368870.001]
  • [Cites] Science. 1992 Feb 21;255(5047):989-91 [1312256.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5822-7 [7694795.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):520-9 [7525492.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] Hepatology. 1996 Mar;23(3):455-64 [8617424.001]
  • [Cites] Cytokine Growth Factor Rev. 1996 Oct;7(3):259-70 [8971481.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Br J Cancer. 1997;76(2):238-43 [9231925.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):933-6 [9714067.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):27-34 [10585578.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jun 1;23(11):1535-47 [16696801.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2903-9 [16782930.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6573-84 [17085673.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] J Med Chem. 2007 Apr 5;50(7):1584-97 [17343372.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1835-45 [17406950.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4779-86 [17947725.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2007;21(6):1089-108 [18070705.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2340-8 [18381441.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2013-9 [18421054.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2992-8 [18565886.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] Invest New Drugs. 2009 Jun;27(3):253-61 [19002384.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1041-8 [15367698.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1898-903 [16622265.001]
  • [Cites] Mol Cancer Ther. 2006 Apr;5(4):995-1006 [16648571.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2231-7 [19307500.001]
  • [Cites] Science. 2009 Jun 12;324(5933):1457-61 [19460966.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3027-35 [19470923.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Sep;64(4):665-72 [19184020.001]
  • [Cites] Lancet Oncol. 2009 Aug;10(8):794-800 [19586800.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4718-26 [19720910.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5513-8 [19858379.001]
  • [Cites] Clin Cancer Res. 2010 Jan 1;16(1):358-66 [20028764.001]
  • [Cites] Br J Cancer. 2010 Jan 5;102(1):68-72 [19935794.001]
  • [Cites] J Clin Oncol. 2010 Jan 10;28(2):207-14 [19949018.001]
  • [Cites] Clin Cancer Res. 2010 Jan 15;16(2):390-7 [20068087.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):48-54 [19932054.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):780-7 [20048182.001]
  • [Cites] Br J Cancer. 2010 Mar 16;102(6):981-6 [20160718.001]
  • [Cites] N Engl J Med. 2010 Apr 8;362(14):1273-81 [20375404.001]
  • [Cites] J Clin Oncol. 2010 Jun 20;28(18):2947-51 [20458043.001]
  • [Cites] Future Oncol. 2010 Jul;6(7):1085-94 [20624120.001]
  • [Cites] J Clin Oncol. 2010 Aug 1;28(22):3617-22 [20606091.001]
  • [Cites] Invest New Drugs. 2011 Dec;29(6):1449-58 [20461441.001]
  • [Cites] Cancer Lett. 2000 May 29;153(1-2):7-12 [10779624.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1358-72 [11054395.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):361-9 [11291072.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3222-30 [11058584.001]
  • [Cites] Am J Surg. 2001 Sep;182(3):298-304 [11587697.001]
  • [Cites] Lab Invest. 2001 Oct;81(10):1439-51 [11598156.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):838-45 [11764072.001]
  • [Cites] Cancer Biother Radiopharm. 2001 Oct;16(5):359-70 [11776753.001]
  • [Cites] Int J Cancer. 2002 Jan 20;97(3):393-9 [11774295.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):1996-2003 [11929816.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):193-202 [12086877.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):37-42 [12131083.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4645-55 [12183421.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] Int J Cancer. 2002 Nov 10;102(2):101-8 [12385004.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7284-90 [12499271.001]
  • (PMID = 21317448.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Drugs, Investigational; 0 / Protein Kinase Inhibitors
  • [Other-IDs] NLM/ PMC3248127
  •  go-up   go-down


26. Malogolowkin MH, Stanley P, Steele DA, Ortega JA: Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol; 2000 Mar;18(6):1279-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and toxicity of chemoembolization for children with liver tumors.
  • PURPOSE: To determine the feasibility, toxicity, and efficacy of hepatic arterial chemoembolization (HACE) in pediatric patients with refractory primary malignancies of the liver.
  • PATIENTS AND METHODS: Six patients with hepatoblastoma (HB), three with hepatocellular carcinoma (HCC), and two with undifferentiated sarcoma of the liver were treated with HACE every 2 to 4 weeks until their tumors became surgically resectable or they showed signs of disease progression.
  • All but one newly diagnosed patient with HCC had previously received systemic chemotherapy.
  • Elevated liver transaminase and bilirubin levels were seen after each one of the 46 courses of HACE.
  • [MeSH-major] Chemoembolization, Therapeutic. Liver Neoplasms / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / therapy. Child. Child, Preschool. Collagen / administration & dosage. Collagen / therapeutic use. Feasibility Studies. Female. Hepatic Artery. Hepatoblastoma / therapy. Humans. Infant. Male. Sarcoma / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10715298.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 121938-23-6 / Angiostat; 9007-34-5 / Collagen
  •  go-up   go-down






Advertisement